The association of statins plus LDL receptor‐targeted liposome‐encapsulated doxorubicin increases <i>in vitro</i> drug delivery across blood–brain barrier cells

Abstract

We suggest that our 'Trojan horse' approach, based on the administration of statins plus a LDL receptor-targeted liposomal drug, might have potential applications in the pharmacological therapy of different brain diseases for which the BBB represents an obstacle.